Schizophrenia News

The American Psychiatric Association on Wednesday announced the launch of PsychPRO 2.0, a mental health registry that offers psychiatrists enhanced options to engage with patients, track outcomes and streamline data for quality reporting.

OxfordVR has announced a successful new virtual reality therapy for patients with mental illnesses such as schizophrenia and mood disorders with psychotic symptoms.

BioXcel Therapeutics has announced the FDA approval of Igalmi, a sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

People with schizophrenia were less likely to have received a COVID-19 booster, while gaps in acquisition were greatest for the first vaccination, according to a retrospective cohort study published in JAMA Psychiatry.

Individuals with serious mental illnesses such as bipolar disorder and schizophrenia may experience greater 10- and 30-year CV risk compared with those without a serious mental illness, researchers reported.

A genomic approach may help identify children at high risk for suicidal thoughts and behaviors, according to results of a cohort study published in JAMA Network Open.

Extreme heat exposure appeared linked to higher rates of mental health-related ED visits, according to results of a case-crossover study published in JAMA Psychiatry.

Researchers reported substantial variability in information on sex-based differences in drug safety and efficacy across trial publications and FDA sources for medications that were approved in 2019 and 2020.

Alkermes announced positive topline results from its phase 3b study of Lybalvi in young adults with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.

Patients with schizophrenia who were treated with 3-monthly paliperidone in a clinical setting required rehospitalization less often, according to a 5-year U.K. mirror image study published in the Journal of Psychiatric Research.